IPS101A / Innopeutics Corporation - LARVOL DELTA

A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product. (clinicaltrials.gov) - P=N/A | N=6 | Recruiting | Sponsor: Innopeutics Corporation | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Gene Therapies • Movement Disorders • Parkinson's Disease

A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product. (clinicaltrials.gov) - P=N/A | N=6 | Not yet recruiting | Sponsor: Innopeutics Corporation

New trial • CNS Disorders • Gene Therapies • Movement Disorders • Parkinson's Disease

Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients (clinicaltrials.gov) - P1 | N=6 | Recruiting | Sponsor: Innopeutics Corporation | Trial completion date: Aug 2027 ➔ Dec 2027 | Initiation date: Feb 2026 ➔ May 2026 | Trial primary completion date: Jul 2026 ➔ Oct 2027 | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Trial completion date • Trial initiation date • Trial primary completion date • CNS Disorders • Gene Therapies • Movement Disorders • Parkinson's Disease